Frontage Holdings Reports Significant Profit Growth in Q3 2025
Frontage Holdings Corp. reported its Q3 2025 financial results, showing a revenue increase to approximately US$191.4 million for the nine months ending September 30, 2025. Net profit surged to US$5.6 million, up from US$0.2 million in 2024, with an adjusted net profit rise of 32.5% to US$12.6 million. The company operates in the pharmaceutical and biotechnology sector, providing drug development services. The current analyst rating for its stock (HK:1521) is a Hold with a price target of HK$1.00.
Frontage Holdings Corp. ( (HK:1521) ) has issued an update.
Frontage Holdings Corporation announced its unaudited financial results for the third quarter of 2025, reporting a slight revenue increase to approximately US$191.4 million for the nine months ending September 30, 2025. The company’s net profit saw a significant rise to US$5.6 million, compared to US$0.2 million in the same period in 2024, with an adjusted net profit increase of 32.5% to US$12.6 million. The announcement highlights the company’s improved financial performance, which may positively impact its market position and investor confidence.
The most recent analyst rating on (HK:1521) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Frontage Holdings Corp. stock, see the HK:1521 Stock Forecast page.
More about Frontage Holdings Corp.
Frontage Holdings Corporation, incorporated in the Cayman Islands, operates in the pharmaceutical and biotechnology industry. The company focuses on providing drug development services, including laboratory and clinical research services, to pharmaceutical and biotech companies.
Average Trading Volume: 480,698
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.22B
For an in-depth examination of 1521 stock, go to TipRanks’ Overview page.
